Our analyses of DPP4 inhibitors included 222 exposed events and did not show any statistically significant association with cholangiocarcinoma (HR vs sulfonylureas 1.15 [95% CI 0.90, 1.46]). The gene discussed is DPP4; the disease is cholangiocarcinoma.